

APPENDIX 3

RELEASED UNDER THE  
OFFICIAL INFORMATION ACT



Reference: PHA16124/1  
Enquiries to: Jared Doncliff

15 April 2016

Kathy Daly  
Team Leader Product Safety  
Medsafe  
Ministry of Health  
PO Box 5013  
WELLINGTON

**FINAL REPORT**

**PROJECT: ADULTERATED MEDICINES PROJECT TESTING**

**Medsafe Reference No.: CAP15052**

**Item No.: AT737 / Exhibit B01**

**Brand name: Tru Weight and Energy**

**Product description: Green capsules in a blister foil**

**Manufacturer details: TruVision Health  
12244 Business Park Drive  
# 115 Draper, UT, 84020**

**Sample obtained from: Simon Williamson  
Senior Investigator  
Medsafe**

**Batch no.: LOT#22963**

**Expiry date: Not stated but number 15306 on blister**

**Date received: 11 March 2016**

**Quantity received: 10 capsules**

**Date of testing: March–April 2016**

The sample was tested, as received, from Medsafe with the following results:

Parameter tested	Result
Screen for Western medicines.	Oxedrine confirmed at approximately 30 mg/capsule contents.

**COMMENTS:**

The capsule contents (approximately 564 mg) were extracted and screened by HPLC and GC/MS with confirmation by LC/MS/MS, LC-QToF and HPLC for the presence of any Western medicines or controlled drugs; in particular those used for weight loss or erectile dysfunction and their analogues, oxedrine, and amphetamine and its analogues.

Please note that the use of a completely validated screen analysis is not possible for these products due to the potential extraction differences with different matrices. While the screen covers many therapeutic compounds with the technique available, no guarantees can be made regarding its ability to detect all such compounds, even those available on the NZ market alone.

  
Jared Doncliff  
Scientist  
Pharmaceutical Programme

  
Tom Sheehan  
Senior Technician  
Pharmaceutical Programme

This report may not be reproduced except in full without the express permission of ESR.



Reference: PHA16124/2  
Enquiries to: Jared Doncliff

15 April 2016

Kathy Daly  
Team Leader Product Safety  
Medsafe  
Ministry of Health  
PO Box 5013  
WELLINGTON

**FINAL REPORT**

**PROJECT: ADULTERATED MEDICINES PROJECT TESTING**

**Medsafe Reference No.: CAP15053**

**Item No.: AT738 / Exhibit B02**

**Brand name: truFIX**

**Product description: Blue capsules in a blister foil**

**Manufacturer details: TruVision Health  
12244 Business Park Drive  
# 115 Draper, UT, 84020**

**Sample obtained from: Simon Williamson  
Senior Investigator  
Medsafe**

**Batch no.: LOT#22963**

**Expiry date: Not stated but number 15306 on blister**

**Date received: 11 March 2016**

**Quantity received: 10 capsules**

**Date of testing: March–April 2016**



The sample was tested, as received, from Medsafe with the following results:


Parameter tested	Result
Screen for Western medicines.	No Western medicines detected.

**COMMENTS:**

The capsule contents (approximately 564 mg) were extracted and screened by HPLC and GC/MS with confirmation by LC/MS/MS, LC-QToF and HPLC for the presence of any Western medicines or controlled drugs; in particular those used for weight loss or erectile dysfunction and their analogues, oxedrine, and amphetamine and its analogues.

Please note that the use of a completely validated screen analysis is not possible for these products due to the potential extraction differences with different matrices. While the screen covers many therapeutic compounds with the technique available, no guarantees can be made regarding its ability to detect all such compounds, even those available on the NZ market alone.

Jared Doncliff  
Scientist  
Pharmaceutical Programme

  
Tom Sheehan  
Senior Technician  
Pharmaceutical Programme

This report may not be reproduced except in full without the express permission of ESR.



Reference: PHA16124/3  
Enquiries to: Jared Doncliff

05 May 2016

Kathy Daly  
Team Leader Product Safety  
Medsafe  
Ministry of Health  
PO Box 5013  
WELLINGTON

**FINAL REPORT**

**PROJECT: ADULTERATED MEDICINES PROJECT TESTING**

**Medsafe Reference No.: CAP15054**

**Item No.: AT739 / Exhibit FP01**

**Brand name:** Tru Weight and Energy

**Product description:** Green capsules in a blister foil

**Manufacturer details:** TruVision Health  
12244 Business Park Drive  
# 115 Draper, UT, 84020

**Sample obtained from:** Simon Williamson  
Senior Investigator  
Medsafe

**Batch no.:** L#23254

**Expiry date:** Not stated but number 15351 on blister

**Date received:** 11 March 2016

**Quantity received:** 10 capsules

**Date of testing:** March–April 2016

The sample was tested, as received, from Medsafe with the following results:

Parameter tested	Result
Screen for Western medicines.	Yohimbine confirmed at approximately 1 mg/capsule contents. Acetylcysteine confirmed at approximately 10 mg/capsule contents.

**COMMENTS:**

The capsule contents (approximately 839 mg) were extracted and screened by HPLC and GC/MS with confirmation by LC/MS/MS, LC-QToF and HPLC for the presence of any Western medicines or controlled drugs; in particular those used for weight loss or erectile dysfunction and their analogues, oxedrine, and amphetamine and its analogues.

Please note that the use of a completely validated screen analysis is not possible for these products due to the potential extraction differences with different matrices. While the screen covers many therapeutic compounds with the technique available, no guarantees can be made regarding its ability to detect all such compounds, even those available on the NZ market alone.

  
Jared Doncliff  
Scientist  
Pharmaceutical Programme

  
Tom Sheehan  
Senior Technician  
Pharmaceutical Programme

This report may not be reproduced except in full without the express permission of ESR.





Reference: PHA16124/4  
Enquiries to: Jared Doncliff

15 April 2016

Kathy Daly  
Team Leader Product Safety  
Medsafe  
Ministry of Health  
PO Box 5013  
WELLINGTON

### FINAL REPORT

**PROJECT:** ADULTERATED MEDICINES PROJECT TESTING

**Medsafe Reference No.:** CAP15055

**Item No.:** AT740 / Exhibit FP02

**Brand name:** truFIX

**Product description:** Blue capsules in a blister foil

**Manufacturer details:** TruVision Health  
12244 Business Park Drive  
# 115 Draper, UT, 84020

**Sample obtained from:** Simon Williamson  
Senior Investigator  
Medsafe

**Batch no.:** L#23245

**Expiry date:** Not stated but number 15349 on blister

**Date received:** 11 March 2016

**Quantity received:** 10 capsules

**Date of testing:** March–April 2016



The sample was tested, as received, from Medsafe with the following results:

Parameter tested	Result
Screen for Western medicines.	No Western medicines detected.

**COMMENTS:**

The capsule contents (approximately 564 mg) were extracted and screened by HPLC and GC/MS with confirmation by LC/MS/MS, LC-QToF and HPLC for the presence of any Western medicines or controlled drugs; in particular those used for weight loss or erectile dysfunction and their analogues, oxedrine, and amphetamine and its analogues.

Please note that the use of a completely validated screen analysis is not possible for these products due to the potential extraction differences with different matrices. While the screen covers many therapeutic compounds with the technique available, no guarantees can be made regarding its ability to detect all such compounds, even those available on the NZ market alone.

  
Jared Doncliff  
Scientist  
Pharmaceutical Programme

  
Tom Sheehan  
Senior Technician  
Pharmaceutical Programme

This report may not be reproduced except in full without the express permission of ESR.



Reference: PHA16177/1  
Enquiries to: Jared Doncliff

15 July 2016

Kathy Daly  
Team Leader Product Safety  
Medsafe  
Ministry of Health  
PO Box 5013  
WELLINGTON

**FINAL REPORT**

**PROJECT: ADULTERATED MEDICINES PROJECT TESTING**

**Medsafe Reference No.: CAP15069**

**Item No.: AT754 / Exhibit FPG1 - 01**

**Brand name:** Tru Weight and Energy

**Product description:** Green capsules in a blister foil

**Manufacturer details:** TruVision Health  
12244 Business Park Drive  
# 115 Draper, UT, 84020

**Sample obtained from:** Simon Williamson  
Senior Investigator  
Medsafe

**Batch no.:** L#23055

**Expiry date:** Not stated but number 15321 on blister

**Date received:** 28 June 2016

**Quantity received:** 5 capsules

**Date of testing:** June–July 2016


The sample was tested, as received, from Medsafe with the following results:

Parameter tested	Result
Screen for Western medicines.	Oxedrine confirmed at approximately 30 mg/capsule contents.

#### COMMENTS:

The capsule contents (approximately 545 mg) were extracted and screened by HPLC and GC/MS with confirmation by LC/MS/MS, LC-QToF and HPLC for the presence of any Western medicines; in particular those used for weight loss or erectile dysfunction and their analogues, and oxedrine.

Please note that the use of a completely validated screen analysis is not possible for these products due to the potential extraction differences with different matrices. While the screen covers many therapeutic compounds with the technique available, no guarantees can be made regarding its ability to detect all such compounds, even those available on the NZ market alone.

  
Jared Doncliff  
Scientist  
Pharmaceutical Programme

  
Tom Sheehan  
Senior Technician  
Pharmaceutical Programme

This report may not be reproduced except in full without the express permission of ESR.





Reference: PHA16177/2  
Enquiries to: Jared Doncliff

15 July 2016

Kathy Daly  
Team Leader Product Safety  
Medsafe  
Ministry of Health  
PO Box 5013  
WELLINGTON

**FINAL REPORT**

**PROJECT: ADULTERATED MEDICINES PROJECT TESTING**

**Medsafe Reference No.: CAP15070**

**Item No.: AT755 / Exhibit BCP -60 - 01**

**Brand name: Tru Weight and Energy**

**Product description: Green capsules in a blister foil**

**Manufacturer details: TruVision Health  
12244 Business Park Drive  
# 115 Draper, UT, 84020**

**Sample obtained from: Simon Williamson  
Senior Investigator  
Medsafe**

**Batch no.: L#23090**

**Expiry date: Not stated but number 15324 on blister**

**Date received: 28 June 2016**

**Quantity received: 5 capsules**

**Date of testing: June–July 2016**

The sample was tested, as received, from Medsafe with the following results:

Parameter tested	Result
Screen for Western medicines.	Oxedrine confirmed at approximately 30 mg/capsule contents.

**COMMENTS:**

The capsule contents (approximately 562 mg) were extracted and screened by HPLC and GC/MS with confirmation by LC/MS/MS, LC-QToF and HPLC for the presence of any Western medicines; in particular those used for weight loss or erectile dysfunction and their analogues, and oxedrine.

Please note that the use of a completely validated screen analysis is not possible for these products due to the potential extraction differences with different matrices. While the screen covers many therapeutic compounds with the technique available, no guarantees can be made regarding its ability to detect all such compounds, even those available on the NZ market alone.

  
Jared Doncliff  
Scientist  
Pharmaceutical Programme

  
Tom Sheehan  
Senior Technician  
Pharmaceutical Programme

This report may not be reproduced except in full without the express permission of ESR.



Reference: PHA16124/2  
Enquiries to: Jared Doncliff

15 April 2016

Kathy Daly  
Team Leader Product Safety  
Medsafe  
Ministry of Health  
PO Box 5013  
WELLINGTON

### FINAL REPORT

**PROJECT:** ADULTERATED MEDICINES PROJECT TESTING

**Medsafe Reference No.:** CAP15053

**Item No.:** AT738 / Exhibit B02

**Brand name:** truFLX

**Product description:** Blue capsules in a blister foil

**Manufacturer details:** TruVision Health  
12244 Business Park Drive  
# 115 Draper, UT, 84020

**Sample obtained from:** Simon Williamson  
Senior Investigator  
Medsafe

**Batch no.:** LOT#22963

**Expiry date:** Not stated but number 15306 on blister

**Date received:** 11 March 2016

**Quantity received:** 10 capsules

**Date of testing:** March–April 2016



The sample was tested, as received, from Medsafe with the following results:


Parameter tested	Result
Screen for Western medicines.	No Western medicines detected.

**COMMENTS:**

The capsule contents (approximately 564 mg) were extracted and screened by HPLC and GC/MS with confirmation by LC/MS/MS, LC-QToF and HPLC for the presence of any Western medicines or controlled drugs; in particular those used for weight loss or erectile dysfunction and their analogues, oxedrine, and amphetamine and its analogues.

Please note that the use of a completely validated screen analysis is not possible for these products due to the potential extraction differences with different matrices. While the screen covers many therapeutic compounds with the technique available, no guarantees can be made regarding its ability to detect all such compounds, even those available on the NZ market alone.

  
Jared Doncliff  
Scientist  
Pharmaceutical Programme

  
Tom Sheehan  
Senior Technician  
Pharmaceutical Programme

This report may not be reproduced except in full without the express permission of ESR.



15 April 2016

Kathy Daly  
Team Leader Product Safety  
Medsafe  
Ministry of Health  
PO Box 5013  
WELLINGTON

**FINAL REPORT**

**PROJECT: ADULTERATED MEDICINES PROJECT TESTING**

**Medsafe Reference No.: CAP15052**

**Item No.: AT737 / Exhibit B01**

**Brand name: Tru Weight and Energy**

**Product description: Green capsules in a blister foil**

**Manufacturer details: TruVision Health  
12244 Business Park Drive  
# 115 Draper, UT, 84020**

**Sample obtained from: Simon Williamson  
Senior Investigator  
Medsafe**

**Batch no.: LOT#22963**

**Expiry date: Not stated but number 15306 on blister**

**Date received: 11 March 2016**

**Quantity received: 10 capsules**

**Date of testing: March–April 2016**

The sample was tested, as received, from Medsafe with the following results:

Parameter tested	Result
Screen for Western medicines.	Oxedrine confirmed at approximately 30 mg/capsule contents.

**COMMENTS:**

The capsule contents (approximately 564 mg) were extracted and screened by HPLC and GC/MS with confirmation by LC/MS/MS, LC-QToF and HPLC for the presence of any Western medicines or controlled drugs; in particular those used for weight loss or erectile dysfunction and their analogues, oxedrine, and amphetamine and its analogues.

Please note that the use of a completely validated screen analysis is not possible for these products due to the potential extraction differences with different matrices. While the screen covers many therapeutic compounds with the technique available, no guarantees can be made regarding its ability to detect all such compounds, even those available on the NZ market alone.

  
 Jared Doncliff  
 Scientist  
 Pharmaceutical Programme

  
 Tom Sheehan  
 Senior Technician  
 Pharmaceutical Programme

This report may not be reproduced except in full without the express permission of ESR.





Reference: PHA16124/4  
Enquiries to: Jared Doncliff

15 April 2016

Kathy Daly  
Team Leader Product Safety  
Medsafe  
Ministry of Health  
PO Box 5013  
WELLINGTON

### FINAL REPORT

**PROJECT:** ADULTERATED MEDICINES PROJECT TESTING

**Medsafe Reference No.:** CA15055

**Item No.:** AT740 / Exhibit FP02

**Brand name:** truFIX

**Product description:** Blue capsules in a blister foil

**Manufacturer details:** TruVision Health  
12244 Business Park Drive  
# 115 Draper, UT, 84020

**Sample obtained from:** Simon Williamson  
Senior Investigator  
Medsafe

**Batch no.:** L#23245

**Expiry date:** Not stated but number 15349 on blister

**Date received:** 11 March 2016

**Quantity received:** 10 capsules

**Date of testing:** March–April 2016

The sample was tested, as received, from Medsafe with the following results:

Parameter tested	Result
Screen for Western medicines.	No Western medicines detected.

**COMMENTS:**

The capsule contents (approximately 564 mg) were extracted and screened by HPLC and GC/MS with confirmation by LC/MS/MS, LC-QToF and HPLC for the presence of any Western medicines or controlled drugs; in particular those used for weight loss or erectile dysfunction and their analogues, oxedrine, and amphetamine and its analogues.

Please note that the use of a completely validated screen analysis is not possible for these products due to the potential extraction differences with different matrices. While the screen covers many therapeutic compounds with the technique available, no guarantees can be made regarding its ability to detect all such compounds, even those available on the NZ market alone.

  
Jared Doncliff  
Scientist  
Pharmaceutical Programme

  
Tom Sheehan  
Senior Technician  
Pharmaceutical Programme

This report may not be reproduced except in full without the express permission of ESR.



Reference: PHA16124/3  
Enquiries to: Jared Doncliff

05 May 2016

Kathy Daly  
Team Leader Product Safety  
Medsafe  
Ministry of Health  
PO Box 5013  
WELLINGTON

**FINAL REPORT**

**PROJECT: ADULTERATED MEDICINES PROJECT TESTING**

**Medsafe Reference No.: CAP15054**

**Item No.: AT739 / Exhibit FP01**

**Brand name: Tru Weight and Energy**

**Product description: Green capsules in a blister foil**

**Manufacturer details: TruVision Health  
12244 Business Park Drive  
# 115 Draper, UT, 84020**

**Sample obtained from: Simon Williamson  
Senior Investigator  
Medsafe**

**Batch no.: L#23254**

**Expiry date: Not stated but number 15351 on blister**

**Date received: 11 March 2016**

**Quantity received: 10 capsules**

**Date of testing: March–April 2016**



The sample was tested, as received, from Medsafe with the following results:

Parameter tested	Result
Screen for Western medicines.	Yohimbine confirmed at approximately 1 mg/capsule contents.  Acetylcysteine confirmed at approximately 10 mg/capsule contents.

**COMMENTS:**

The capsule contents (approximately 839 mg) were extracted and screened by HPLC and GC/MS with confirmation by LC/MS/MS, LC-QTOF and HPLC for the presence of any Western medicines or controlled drugs; in particular those used for weight loss or erectile dysfunction and their analogues, oxedrine, and amphetamine and its analogues.

Please note that the use of a completely validated screen analysis is not possible for these products due to the potential extraction differences with different matrices. While the screen covers many therapeutic compounds with the technique available, no guarantees can be made regarding its ability to detect all such compounds, even those available on the NZ market alone.

  
Jared Doncliff  
Scientist  
Pharmaceutical Programme

  
Tom Sheehan  
Senior Technician  
Pharmaceutical Programme

This report may not be reproduced except in full without the express permission of ESR.